Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Taxes (2016 - 2025)

Historic Change in Taxes for Ani Pharmaceuticals (ANIP) over the last 12 years, with Q3 2025 value amounting to -$12.5 million.

  • Ani Pharmaceuticals' Change in Taxes fell 28764.29% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 5300.61%. This contributed to the annual value of -$1.4 million for FY2024, which is 11180.05% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Change in Taxes stood at -$12.5 million for Q3 2025, which was down 28764.29% from -$10.9 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Change in Taxes registered a high of $12.9 million during Q4 2024, and its lowest value of -$14.3 million during Q2 2024.
  • For the 5-year period, Ani Pharmaceuticals' Change in Taxes averaged around -$692631.6, with its median value being -$247000.0 (2021).
  • In the last 5 years, Ani Pharmaceuticals' Change in Taxes soared by 1553877.55% in 2023 and then tumbled by 394220.96% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Taxes (Quarter) stood at -$637000.0 in 2021, then soared by 92.31% to -$49000.0 in 2022, then skyrocketed by 15538.78% to $7.6 million in 2023, then surged by 69.9% to $12.9 million in 2024, then tumbled by 197.63% to -$12.5 million in 2025.
  • Its Change in Taxes stands at -$12.5 million for Q3 2025, versus -$10.9 million for Q2 2025 and $7.4 million for Q1 2025.